A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1

Trial Profile

A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMAGINE-1
  • Sponsors Amgen
  • Most Recent Events

    • 16 Feb 2018 Results from this study were presented at the 76th annual American Academy of Dermatology meeting according to an Ortho Dermatologics media release.
    • 16 Feb 2018 Pooled results from AMAGINE 1, 2 and trials presented at the 76th annual American Academy of Dermatology meeting according to a LEO Pharma media release.
    • 12 Oct 2017 Results published in an Ortho Dermatologics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top